There are currently 2647 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572
Recruiting
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
04/23/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
Register for Updates
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
NCT04404881
Recruiting
This research study is studying to see whether bevacizumab may treat chronic bleeding and iron deficiency anemia in Hereditary Hemorrhagic Telangiectasia (HHT). Hereditary Hemorrhagic Telangiectasia (HHT) is a disorder that causes abnormal blood vessel formation. In HHT, there is a mutation in the TGF-β pathway, which results in an increase of vascular endothelial growth factor (VEGF) levels. An increase in VEGF levels can result in poorly formed blood vessels that have a higher rate of bleedin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hereditary Hemorrhagic Telangiectasia
Register for Updates
Mapping Auricular Vagus Nerve Circuitry
NCT00200889
Recruiting
This study will determine how noninvasive nerve stimulation affects human brain, stomach, and autonomic activity.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/22/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Healthy
Register for Updates
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
NCT03219450
Recruiting
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophosphamide * Pembrolizumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Lymphocytic Leukemia
Register for Updates
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
NCT06138561
Recruiting
The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its ability to predict outcomes in older participants undergoing cancer treatments. Additionally, investigators are evaluating the differential impact of treatments on quality of life in an older and at ri... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/19/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
Register for Updates
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
NCT01656603
Recruiting
This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.
Gender:
ALL
Ages:
All
Trial Updated:
04/17/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Infusion Reactions
Register for Updates
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05201638
Recruiting
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/17/2024
Locations: Boston Clinical Trials, Boston, Massachusetts
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
NCT05555589
Recruiting
The objective of this study is to compare the safety and efficacy of RGN-259 to placebo for the treatment of Neurotrophic Keratopathy (NK)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Tufts Medical Center, Department of Ophthalmology, Boston, Massachusetts
Conditions: Neurotrophic Keratopathy
Register for Updates
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
NCT05941507
Recruiting
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refractory to standard of care, or for whom no standard of care exists. After the MTD and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor types... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Solid Tumors
Register for Updates
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
NCT04816604
Recruiting
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/16/2024
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
NCT01790152
Recruiting
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
Gender:
ALL
Ages:
All
Trial Updated:
04/16/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Hodgkin Lymphoma in Remission, Leukemia in Remission, Lymphoblastic Lymphoma, Osteosarcoma, Recurrent Leukemia, Recurrent Lymphoma, Recurrent Malignant Neoplasm
Register for Updates
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
NCT05389215
Recruiting
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/16/2024
Locations: Tufts Medical Center, Boston, Massachusetts +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates